eltrombopag

an oral, nonpeptide thrombopoietin receptor agonist

Also Known As:

(1,1'-biphenyl)-3-carboxylic acid, 3'-((2Z)-(1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene)hydrazino)-2'-hydroxy-; DDL-701; Promacta; Revolade; SB-497 115; SB-497-115; SB497115

Networked: 739 relevant articles (141 outcomes, 147 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Bussel, James B: 20 articles (01/2022 - 11/2007)
2.	Young, Neal S: 14 articles (01/2022 - 07/2012)
3.	Townsley, Danielle M: 12 articles (01/2021 - 07/2013)
4.	Dunbar, Cynthia E: 11 articles (01/2022 - 07/2012)
5.	Theodore, Dickens: 11 articles (01/2017 - 11/2007)
6.	Winkler, Thomas: 10 articles (01/2022 - 12/2016)
7.	Scheinberg, Phillip: 10 articles (01/2021 - 07/2012)
8.	Desmond, Ronan: 9 articles (01/2022 - 07/2012)
9.	Brainsky, Andres: 9 articles (01/2015 - 12/2011)
10.	Wong, Raymond S M: 8 articles (01/2022 - 01/2015)

Related Diseases

1.	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 12/01/2008 - "Randomized trials have shown the short-term efficacy of eltrombopag in elevating the platelet count of most adult patients with immune thrombocytopenia unresponsive to at least one standard treatment. " 03/01/2015 - "Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia." 01/01/2023 - "Eltrombopag (ELT) is effective and safe in adult persistent/chronic immune thrombocytopenia (p/cITP); a proportion could achieve a sustained response off treatment (SRoT); however, data on children are lacking. " 03/01/2014 - "Eltrombopag was suggested to be effective in perioperative management in a patient with idiopathic thrombocytopenic purpura undergoing cardiovascular surgery. " 03/01/2019 - "Eltrombopag can quickly promote platelets and be conveniently used, thereby providing a new treatment option for patients with immune thrombocytopenia. "
2.	Thrombocytopenia (Thrombopenia) 06/01/2014 - "Thus, short-term eltrombopag administration may not accelerate HCC proliferation and may be beneficial for invasive HCC treatment in cirrhotic patients with thrombocytopenia." 01/01/2010 - "Based on the current and emerging evidence, a review of the pharmacologic basis, pharmacokinetics, therapeutic efficacy, safety profile and future considerations of eltrombopag in the context of HCV-related thrombocytopenia is given in this article. " 01/01/2021 - "Eltrombopag was effective and safe in overcoming post-HSCT primary thrombocytopenia in our patient." 01/01/2021 - "Eltrombopag is effective and safe in paediatric patients with thrombocytopenia after HSCT. " 01/01/2019 - "Eltrombopag is safe and effective for patients with HCV-associated thrombocytopenia. "
3.	Aplastic Anemia (Anemia, Hypoplastic) 01/01/2021 - "Eltrombopag has been added to first-line treatment of immune aplastic anaemia (AA), resulting in higher responses. " 02/01/2019 - "Eltrombopag seems to be effective in treating patients with aplastic anemia in several clinical trials. " 01/01/2021 - "Correction to: Eltrombopag is effective in patients with relapse/refractory aplastic anemia-report from a single center in China." 12/01/2020 - "Eltrombopag is effective in patients with relapse/refractory aplastic anemia-report from a single center in China." 01/01/2020 - "Background and purpose: Eltrombopag (ELT) can be effective in the treatment of relapse/refractory aplastic anemia (AA) patients. "
4.	Hemorrhage 01/01/2020 - "Four patients with clinically significant spontaneous bleeding entered a program of long-term eltrombopag administration (16 additional weeks): all of them obtained remission of mucosal hemorrhages, with the remission persisting throughout the treatment period. " 11/01/2017 - "The efficacy of eltrombopag did not differ significantly between children and adults except for incidence of any bleeding (RR: 0.83 vs 0.51; P = .008). " 12/01/2020 - "The trial hints toward the positive effect of eltrombopag in the cessation of bleeding manifestation. " 12/01/2020 - "The bleeding manifestations for thirteen out of fourteen grade-II DHF patients were subsided within Day-7 who received eltrombopag, whereas four out of ten grade-II DHF patients with PLT counts lower than the lower normal limit in the control group showed intermittent bleeding symptoms throughout the trial period. " 04/01/2013 - "Across all studies, bleeding at baseline ranged from 50 to 73% for eltrombopag-treated patients; by week 2, bleeding had decreased, ranging from 26 to 39%. "
5.	Cytopenia 12/03/2023 - "The use of eltrombopag for post-CAR T cytopenias might be effective in a high-risk patient population but requires further study." 01/01/2020 - "As a single agent, eltrombopag in doses up to 150 mg daily improved cytopenias in 40 to 50% in those who failed initial IST, which associated with higher marrow cellularity, suggesting a pan-stimulatory marrow effect. " 01/01/2018 - "Based on the positive results obtained in these 2 patients, we suggest that eltrombopag may have a favorable effect on unilineage cytopenias such as PRCA. " 12/03/2023 - "Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias." 01/01/2020 - "These preliminary data confirm that eltrombopag is able to rescue multilineage haematopoiesis in patients with treatment-refractory cytopenias after allogeneic HSCT."

Related Drugs and Biologics

1.	Inosine Triphosphate (ITP)
2.	romiplostim
3.	Thrombopoietin Receptors
4.	Thrombopoietin (c-mpl Ligand)
5.	Cyclosporine (Ciclosporin)
6.	Antilymphocyte Serum (Anti-Thymocyte Globulin)
7.	Antiviral Agents (Antivirals)
8.	avatrombopag
9.	Azacitidine (5 Azacytidine)
10.	Intravenous Immunoglobulins (IVIG)

Related Therapies and Procedures

1.	Therapeutics
2.	Hematopoietic Stem Cell Transplantation
3.	Platelet Transfusion (Blood Platelet Transfusions)
4.	Stem Cell Transplantation
5.	Splenectomy